[Business Wire] Emerson Electric Co. (NYSE:EMR) announced the following senior management appointments and changes, effective after Emerson’s February 3, 2015 board of directors meeting:
Edgar M. (Ed) Purvis has been appointed the chief operating officer for Emerson. He will report to Chairman and CEO David N. Farr and will be a member of Emerson’s Office of the Chief Executive. Purvis has served as executive vice president and business leader for Emerson Climate Technologies since 2008. He began his Emerson career in 1983 at the Copeland business unit and has held positions of increasing responsibility at Copeland and Emerson Climate Technologies Refrigeration. To view the full article click here.
Emerson Electric Co. (EMR), On 11/4/2014, EMR reported 4 quarter 2014 earnings of $1.30 per share. This result beat the $1.23 consensus of the 24 analysts covering the company and beat last year’s 4 quarter results by 10.17%. The next earnings announcement is expected on 02/03/2015.
EMR’s PE ratio is in-line with the Scientific & Technical Instr. industry average and implies that investors do not see anything special about this company’s prospects. Additionally, during the past year, earnings growth has outpaced its historical five year growth rate.
Emerson Electric Co. (EMR)‘s PE ratio is among the lowest of any stock in the Semiconductors industry and signals that investors have not been willing to pay a premium for this company’s business prospects. Additionally, during the past year, earnings growth has outpaced its historical five year growth rate.
In terms of ratings, there are twenty three analysts that cover the stock which have provided Q1 2015 earnings per share estimates. The consensus anticipated number for the upcoming quarter is $0.73. The highest estimate is $0.77 while the lowest is $0.78. The company has a one year EPS growth rate of 10.00% and a five year EPS growth rate of 6.17%.
About Emerson Electric Co. (NYSE:EMR)
Emerson Electric Co. is a specialty pharmaceutical company primarily focused on the commercialization of oncology treatment and oncology supportive care pharmaceutical products. The Company’s primary focus is on the commercialization of oncology treatment and oncology supportive care pharmaceutical products, including Soltamox, an oral solution of tamoxifen citrate; cancer support therapeutics, including Gelclair, indicated for the treatment of oral mucositis, and Bionect, for the management of irritation of the skin as well as first and second degree burns, and Three Mission Pharmacal products, including Ferralet 90 (for anemia) Binosto (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis) and Aquoral (for cancer related dry mouth). The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy.